Angiotensin II downregulates MicroRNA-145 to regulate kruppel-like factor 4 and myocardin expression in human coronary arterial smooth muscle cells under high glucose conditions

Molecular Medicine

Volumn 21, Issue , 2015, Pages 616-628

  Shyu, Kou Gi ^a,b   Cheng, Wen Ping ^a   Wang, Bao Wei ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ENALAPRILAT; GLUCOSE; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 4; MICRORNA 145; MITOGEN ACTIVATED PROTEIN KINASE 1; MYOCARDIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; KRUPPEL LIKE FACTOR; MICRORNA; MIRN145 MICRORNA, HUMAN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CAROTID ARTERY INJURY; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DOWN REGULATION; ENZYME REPRESSION; EXPERIMENTAL BALLOON CATHETER INJURY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RESISTANCE; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; CORONARY BLOOD VESSEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; TUNICA MEDIA;

ANGIOTENSIN II; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NUCLEAR PROTEINS; RATS; TRANS-ACTIVATORS; TUNICA MEDIA; VALSARTAN;

EID: 84945933536     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2015.00041     Document Type: Article

References (32)

1. Paneni F, Beckman JA, Creager MA, Cosentino F. (2013) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part 1. Eur. Heart J. 34:2436-46.
2. Shntikumarn S, Caporali A, Emanueli C. (2012) Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc. Res. 93:583-93.
3. Zampetaki A, Mayr M. (2012) MicroRNAs in vascular and metabolic disease. Circ. Res. 110:508-22.
4. Boettger T, et al. (2009) Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J. Clin. Invest. 119:2634-47.
5. Cordes KR, et al. (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 460:705-10.
6. Cheng Y, et al. (2009) MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 105:158-66.
7. Xin M, et al. (2009) MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes. Dev. 23:2166-78.
8. Wang Z, et al. (2004) Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature. 428:185-9.
9. Garvey SM, Sinden DS, Schoppee Bortz PD, Wamhoff BR. (2010) Cyclosporine up-regulates Kruppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo. J. Pharmacol. Exp. Ther. 333:34-42.
10. Zanella MT, Kohlmann O Jr., Ribeiro AB. (2001) Treatment of obesity, hypertension and diabetes syndrome. Hypertension. 38:705-8.
11. Shyu KG, Wang BW, Wu GJ, Lin CM, Chang H. (2013) Mechanical stretch via transforming growth factor-g1 activates microRNA208a to regulate endoglin expression in cultured rat cardiac myoblasts. Eur. J. Heart Fail. 15:36-45.
12. Cheng WP, Hung HF, Wang BW, Shyu KG. (2008) The molecular regulation of GADD153 in apoptosis of cultured vascular smooth muscle cells by cyclic mechanical stretch. Cardiovasc. Res. 77:551-9.
13. Wang BW, Chang H, Lin S, Kuan P, Shyu KG. (2003) Induction of matrix metalloproteinase-14 and-2 by cyclical mechanical stretch is mediated by tumor necrosis factor-nnin cultured human umbilical vein endothelial cells. Cardiovasc. Res. 59:460-9.
14. Chang H, et al. (2003) GL-331 inhibits HIF-1.expression in a lung cancer model. Biochem. Biophys. Res. Commun. 302:95-100.
15. Shyu KG, Wang BW, Kuan P, Chang H. (2008) RNA Interference for discoidin domain receptor 2 attenuates neointimal formation in balloon injured rat carotid artery. Arterioscler. Thromb. Vasc. Biol. 28:1447-53.
16. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies, National Research Council of the National Academies. (2011) Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academic Press.
17. Hu B, et al. (2014) Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype. PLoS One. 9:e96338.
18. Davies-Dusenbery BN, et al. (2011) Downregulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-ggand bone morphogenetic protein 4. J. Biol. Chem. 286:28097-110.
19. Rangrez AY, Massy ZA, Meuth VML, Metzinger L. (2011) miR-143 and miR-145: Molecular keys to switch the phenotype of vascular smooth muscle cells. Circ. Cardiovasc. Genet. 4:197-205.
20. Shu HJ, Wen JK, Miao SB, Liu Y, Zheng B. (2012) KLF5 and hhLIM cooperatively promote proliferation of vascular smooth muscle cells. Mol. Cell Biochem. 367:185-94.
21. Bartel DP. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281-97.
22. Natarajan R, Putta S, Kato M. (2012) MicroRNAs and diabetic complication. J. Cardiovasc. Trans. Res. 5:413-22.
23. Small EM, Olson EN. (2007) Pervasive roles of microRNAs in cardiovascular biology. Nature. 469:36-342.
24. Ji R, et al. (2007) MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ. Res. 100:1579-88.
25. Rzucidlo EM, Martin KA, Powell RJ. (2007) Regulation of vascular smooth muscle cell differentiation. J. Vasc. Surg, 45:A25-32.
26. Hutcheson R, et al. (2013) MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 33:727-36.
27. Natarajan R, Scott S, Bai W, Yerneni KKV, Nadler J. (1999) Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Hypertension. 33:378-84.
28. Sodhi CP, Kanwar YS, Sahai A. (2003) Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am. J. Physiol. Heart Circ. Physiol. 284:H846-52.
29. Xue, et al. (2013) H2S inhibits hyperglycemiainduced intrarenal renin-angiotensin system activation via attenuation of reactive oxygen species generation. PLoS One. 8:e74336.
30. Wen et al. (2014) miRNA-145 is involved in the development of resistin-induced insulin resistance in HepG2 cells. Biochem. Biophys. Res. Commun. 445:517-23.
31. Norta GD, et al. (2012) MicroRNA 143-145 deficiency impairs vascular function. Int. J. Immunol. Pharmacol. 25:467-84.
32. Lovren F, et al. (2012) MicroRNA-145 targeted therapy reduces atherosclerosis Circulation. 126(11 Suppl 1):S81-90.